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Abstract 
 
Objectives: The effect of implant removal after internal fixation of a femoral neck fracture on 
physical functioning was analyzed. Characteristics of patients who had their implant removed 
were studied, as it is currently unknown in which type of patients implants are removed and 
what effect removal has on function. 
Design: Secondary cohort study alongside a RCT. 
Setting: Multicenter study in 14 hospitals. 
Patients and Intervention: Patients who had their implant removed after internal fixation of 
a femoral neck fracture are compared with patients who did not. 
Main outcome measurements: Patient characteristics and quality of life (Short Form-12 
(SF-12), Western Ontario McMaster Osteoarthritis Index (WOMAC)) were compared. 
Matched pairs were selected based on patient/fracture characteristics and pre-fracture physical 
functioning. 
Results: Of 162 patients, 37 had their implant removed (23%). These patients were younger 
(median age 67 versus 72 years, P=0.024) and more often independently ambulatory pre-
fracture (100% versus 84%, P=0.008) than patients who did not. They more often had evident 
implant back-out on X-rays (54% versus 34%, P=0.035), possibly related to a higher rate of 
Pauwels 3 fractures (41% versus 22%, P=0.032). In time, quality of life improved more in 
implant-removal patients (+2 versus -4 points SF-12 (physical component), P=0.024; +9 
versus 0 points WOMAC, P=0.019).  
Conclusions: Implant removal after internal fixation of a femoral neck fracture positively 
influenced quality of life. Implant-removal patients were younger and more often 
independently ambulatory pre-fracture, more often had a Pauwels 3 fracture, and an evident 
implant back-out. Implant removal should be considered liberally for these patients if pain 
persists or functional recovery is unsatisfactory. 
Level of evidence: II 
Keywords: Femoral neck fracture, hip fracture, internal fixation, implant removal, patient 
functioning.
Introduction 
 
Internal fixation of femoral neck fractures can sometimes result in long-term physical 
limitations and pain, even if fractures have healed uneventfully.1 These limitations can be 
caused by physical changes such as tissue damage, scarring, and loss of muscle strength due 
to the injury and surgical exposure, or femoral neck shortening due to impaction at the 
fracture site.1 The implant can cause local irritation and functional impairment.2-4 In some 
patients with persistent complaints the implant is therefore removed after fracture healing. 
The rate of implant removal after internal fixation of femoral neck fractures is unknown. 
Reported implant removal rates  after internal fixation of fractures at various anatomical 
locations including the hip, ranges from 16% to 81%.5,6  
Guidelines on when to remove implants do not exist, mainly due to a lack of evidence. 
Several surveys among surgeons have indicated that patient related factors (e.g., local 
irritation, pain, (unexplained) complaints, or patients request), possible carcinogenic/toxic, or 
unknown systemic effects, and expected problems with later removal due to bony overgrowth 
are considered reasons for implant removal.2-4,7 A greater risk of future fractures due to stress 
shielding may also be a reason.8,2,4 General reasons not to remove implants could be the risk 
of tissue or nerve damage, or an adverse event (mainly wound infection or hematoma) 
associated with secondary surgery. The costs of a second surgery and rehabilitation period 
may also play a role. Two cohort studies have indicated that removal of implants, at various 
anatomical locations, improves pain relief and function.9,10 In other studies, however, the 
relief of complaints was not found.11,2,7 
To the best of our knowledge, implant removal after internal fixation of femoral neck 
fractures has not been reported in detail. The effect of implant removal on physical 
functioning in these patients is therefore unknown. It is also unknown which patients are 
candidates for removal. Therefore, the aim of this study was to analyze the effect of implant 
removal after internal fixation of a femoral neck fracture on physical functioning. 
Characteristics of patients who had their implant removed were also described.
Patients and Methods 
 
Population 
This study was a secondary cohort study to the Dutch sample of an international randomized 
controlled trial, the FAITH trial (Fixation using Alternative Implants for the Treatment of Hip 
fractures, NCT00761813).12 The primary objective of the FAITH trial was to assess the 
impact of internal fixation implants (sliding hip screw versus multiple cancellous screws) on 
rates of revision surgery at two years in elderly patients with femoral neck fractures (i.e., AO 
type 31-B fractures).13 In the Netherlands 14 hospitals participated and randomized 250 
patients between February 2008 and August 2009. These patients were adults aged >50 years, 
who were ambulatory and not cognitively impaired pre-fracture. Patients had either (a) an 
undisplaced fracture, or (b) a displaced fracture in ASA 1-2 patients, who were 50-80 years 
old, with a fracture that could be reduced closed.14 Surgeries were either performed or 
supervised by an experienced surgeon. All patients were allowed weight bearing as tolerated 
after surgery. 
In the current study, all Dutch FAITH patients who healed after internal fixation were 
studied. Patients who had their implant removed were compared with patients who did not 
(control group). Patients who had a revision surgery due to implant failure, non-union, or 
avascular necrosis (i.e., implant switch or salvage arthroplasty) were excluded. Patients who 
had a primary arthroplasty due to an unsuccessful fracture reduction were also excluded. The 
indication for implant removal was persisting pain and/or functional limitation in various 
degrees, which was considered to be (possibly) caused by the implant. The decision to remove 
the implant was left to the discretion of the treating surgeon. The implant was removed 
approximately one year after the fracture surgery if the fracture had healed. 
 
Data and measurements 
Patient baseline characteristics, fracture characteristics, and follow-up data, including health-
related quality of life (Short Form-12 (SF-12)) and disease-specific quality of life scores 
(Western Ontario McMaster Osteoarthritis Index (WOMAC)) were available from the FAITH 
trial.15,16 In order to calculate the baseline (i.e., pre-fracture) score, patients completed the 
questionnaires asking for their pre-fracture quality of life within one week after the fracture. 
SF-12 scores were converted to a norm-based score and compared with the norms for the 
general population of the United States (1998), as weighing factors for the Dutch population 
were not available.  
 X-rays were also collected. In order to study the relation between implant back-out 
and implant removal, a single investigator scored all X-rays for signs of ‘evident implant 
back-out’. This was defined as back-out with evident increasing distance of the distal end of 
the implant in relation to the lateral femoral cortex (Figure 1). 
 
Statistical analysis 
Analyses were performed using the Statistical Package for the Social Sciences (SPSS, version 
16.0, SPSS Inc., Chicago, IL, USA).Baseline and fracture characteristics, as well as SF-12 
and WOMAC scores at baseline (i.e., pre-fracture) and after two years follow-up were 
compared. The change in scores between these two moments was calculated using the 
formula: Change Score = Score 2 years – Score baseline. Continuous data are presented as medians 
with percentiles, categorical variables as numbers and percentage. In the crude analysis, 
groups were compared using a Mann Whitney U-test (continuous data) or a Chi-squared test 
(categorical data). 
In order to study the effect of implant removal on patient functioning more 
specifically, a matched pair analysis was performed. A matched control was searched for all 
implant removal patients with complete follow-up data. Controls were considered adequate if 
they had a comparable age (<5 years difference), identical ASA score (American Society of 
Anesthesiologists classification), pre-fracture living status, pre-fracture use of ambulatory 
aids, fracture classification (Garden I/II versus III/IV and Pauwels 1-2 versus Pauwels 3), type 
of implant, and a comparable WOMAC score at baseline (<5 points difference). Use of a 
single control for multiple patients was allowed. In the matched pair analysis, SF-12 and 
WOMAC scores for the implant removal patients were calculated for the follow-up moment 
immediately before implant removal (mostly 12 or 18 months after initial fracture surgery) 
and at the first follow up moment after removal (mostly 18 or 24 months after initial fracture 
surgery). For the matched control the scores at the same follow-up moment in time were used. 
The change in scores between these two moments was calculated using the formula: Change 
Score = Score after removal – Score before removal. Groups were compared using a Wilcoxon signed 
rank test (continuous data). Results with P<0.05 (two-sided test) were regarded statistically 
significant.
Results 
 
Patient, fracture, and treatment characteristics 
Of the initial 250 patients, 162 patients healed uneventfully after internal fixation and were 
included. The remaining 88 patients were excluded, mainly since they had an arthroplasty as 
salvage procedure (N=69) or during primary surgery (N=16; Figure 2). 
 Patient, fracture, and treatment characteristics are shown in Table 1. Of the 162 
patients who healed after internal fixation 37 patients had their implant removed (23%), at a 
median of 15 months after initial fracture surgery. Eight patients had an implant removal 
associated adverse event (22%); four patients sustained a bleeding or hematoma (11%), two 
patients a trochanteric bursitis (5%), one patient a urinary retention (3%), and one patient a 
wound infection (3%). 
Patients who had their implant removed were significantly younger than patients who 
did not (median age 67 versus 72 years, P=0.024) and significantly more often  independent 
ambulatory pre-fracture (100% versus 84%  independently ambulatory, P=0.008). The 
implant removal patients also significantly more often had a Pauwels 3 type fracture (41% 
versus 22%, P=0.031) and an evident implant back-out on X-rays (54% versus 34%, 
P=0.035). 
 
Crude analysis of patient self-reported health-related and disease-specific quality of life (SF-
12 and WOMAC) 
At baseline (i.e., pre-fracture) patients who had their implant removed had significantly 
higher SF-12 scores than patients who healed without implant removal (107 versus 102 
points, P=0.038). Especially the physical component summary scores were higher 
(Supplemental Table 1). WOMAC scores were not significantly different at baseline (97 
versus 95 points, P=0.101). 
 After two years the SF-12 and WOMAC scores had decreased in patients who had 
their implant removed as well as in the patients who did not (Table 2). Again, this was mostly 
apparent in the physical component and function scores (Table 2). However, there was no 
significant difference in change between the groups; median change in SF-12 score -3 versus -
3 points (P=0.700) and WOMAC score -3 versus -4 points (P=0.427; Table 2). 
 
Matched pair analysis 
Of the 37 implant removal patients, five patients could not be included in the matched pair 
analysis because they did not have complete follow-up data. A match could be found for 22 of 
the remaining patients (Figure 2). The matched pairs had similar characteristics, as expected 
(Table 1). The only difference was a higher percentage of patients with evident implant back-
out in the implant removal group (50% versus 9%, P=0.004). 
At the follow-up moment directly before the implant removal (i.e., mostly 12 or 18 
months after initial fracture surgery), the implant removal patients reported significantly 
lower physical functioning scores than the patients who had their implant retained. This is 
reflected in the SF-12 physical component summary score (44 versus 53 points, P=0.005) and 
all WOMAC sub-scores (pain 83 versus 100 points, P=0.001; stiffness 75 versus 100 points, 
P=0.010; function 82 versus 98 points, P=0.002; Table 3). At the follow-up moment directly 
after the implant removal (i.e., mostly 18 or 24 months after initial fracture surgery),  only a 
significantly lower WOMAC pain sub-score in the implant removal group remained (90 
versus 98 points, P=0.036). Despite the second surgery and rehabilitation period, the implant 
removal patients still had an improvement of their physical functioning scores in the period of 
their implant removal, whereas the control group had not. This is reflected in an improvement 
in SF-12 physical component summary score (2 versus -4 points, P=0.024), WOMAC 
function sub-score (10 versus 0 points, P=0.030) and WOMAC total score (9 versus 0 points, 
P=0.019; Table 3).
Discussion 
 
Implant removal after internal fixation of a femoral neck fracture had a significantly positive 
effect on patient functioning. The functional outcome scores of both the SF-12 and the 
WOMAC improved significantly more in the patients who had their implant removed than in 
the patients who did not, in a similar time period. Even though the implant removal patients 
were significantly more impaired than the control group before implant removal, they had 
similar general health-related and disease-specific quality of life after two years follow-up, 
which could be related to the implant removal. This positive effect of implant removal is 
confirmed in other studies on implant removal for different fractures.9,10 The positive effect of 
implant removal may in fact even have been underestimated, as quality of life measurements 
were sometimes performed shortly after the implant removal surgery (i.e., <6 months). 
Patients could therefore still have been rehabilitating from the second surgery at the time of 
follow-up. This may also explain why the WOMAC pain sub-scores were not significantly 
different between the groups after implant removal, although P-values approximated the 0.05 
significance threshold.  
 The current study again emphasizes that disease-specific quality of life scores (e.g., 
WOMAC) seem more appropriate in hip fracture patients than general health-related quality 
of life scores (e.g., SF-12). The problem in the hip fracture population is a complex 
assortment of issues ranging from baseline health and frailty, social isolation and support, 
mental status and joint function and pain, which are all expressed in general health-related 
quality of life. The change in physical functioning through time was better expressed in the 
WOMAC total and sub-scores, than in the SF-12 total and sub-scores (Table 3). 
Patients who had their implant removed after internal fixation of a femoral neck 
fracture were significantly younger and more often independent ambulatory pre-fracture than 
patients who did not. They also reported a better pre-fracture general health-related quality of 
life. This suggests that these patients were probably more mobile and active, and were 
therefore more impaired by the implant. Generally, it is likely that this patient category strived 
for a better outcome and performance level, and were less put off by the idea of a second 
surgery and rehabilitation period. In a previous study on implant removal after femur 
fractures, age also influenced the likelihood of removal.6 
As expected, implant back-out was observed more often in patients who had their 
implant removed. Weight bearing can cause impaction at the fracture site and may result in 
femoral neck shortening, causing the implant to back-out.1 The implant is then interfering 
with the surrounding soft tissues (i.e., abductor muscles and fascia lata). This can result in 
pain and functional impairment, causing patients to have their implant removed. Apparently, 
implant back-out does not always cause complaints severe enough to decide on implant 
removal, as 34% of patients in the control group retained their implant despite an evident 
implant back-out. In 46% of patients, on the other hand, the implant was removed without 
signs of an evident implant back-out. Implant back-out is therefore not always the cause of 
complaints. Implant removal patients more often had a Pauwels 3 type fracture. A previous 
study already indicated a Pauwels 3 type fracture as risk factor for femoral neck shortening 
and therefore causing increased implant back-out.1 
The reason for implant removal was pain and/or functional impairment in all patients.  
It was therefore expected that SF-12 and WOMAC scores before implant removal were 
significantly worse in the implant removal patients, as shown in the results. 
Implant removal seems a safe procedure with minimal risk. None of the adverse events 
that occurred were severe or caused permanent disability. The argument of extra costs seems 
refutable in this population, as a previously published cost analysis of this study group 
indicated that the implant removal patients were actually less expensive than the patients who 
healed without removal (€10,066 versus €17,405 after two years follow-up).14 However, a 
selection bias may have played a role. 
The main limitation of this study is the relatively low number of patients included, 
mainly in the matched pair analysis. If the study would be repeated with a higher number of 
patients and a longer period of follow-up after implant removal, it is likely that the positive 
effect of implant removal will even be more obvious. However, this is still the first study 
providing evidence on this topic, and significant effects are seen, even in this relatively small 
population. It would also be interesting to measure the effect on physical functioning using 
more objective parameters, such as gait parameters or muscle strength.1 Unfortunately, our 
results can only prove a positive effect of implant removal for the patients who were selected 
in this study based on their symptoms and general condition. These patients were relatively 
young, healthy and independent pre-fracture. Results should therefore not be generalized. 
 
In conclusion, implant removal after internal fixation of a femoral neck fracture had a 
significantly positive effect on patient functioning in this study. Patients who had their 
implant removed were younger , more often independently ambulatory pre-fracture, had a 
Pauwels 3 type fracture, and an evident implant back-out than patients who did not. Given the 
positive effects on patient functioning in this study, we suggest that implant removal should 
be considered more liberally in these patients, if there are persistent complaints of pain or 
unsatisfactory functional recovery after internal fixation of a femoral neck fracture.  
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Figure legends 
 
 
Figure 1. Example of evident implant back-out 
 
 Figure 2. Flowchart of patients participating in this study  
 
Tables 
 
Table 1. Patient characteristics 
 Crude analysis   Matched pair analysis   
 Implant removed 
(N=37) 
Implant retained 
(N=125) 
P-value Implant removed 
(N=22) 
Implant retained 
(N=22) 
P-value 
Age (years) 1* 67 (60-73) 72 (62-79) 0.024 67 (61-74) 64 (60-72) 0.123 
BMI (kg/m²)1 24 (21-26) 24 (22-26) 0.522 23 (20-26) 24 (21-28) 0.338 
ASA >22* 2 (5) 21 (17) 0.088 0 (0) 0 (0) 1.000 
Female2 19 (51) 71 (57) 0.577 12 (55) 13 (59) 1.000 
Displaced fracture (Garden III-IV)2* 18 (49) 38 (30) 0.050 11 (50) 11 (50) 1.000 
Pauwels 3 fracture2* 15 (41) 27 (22) 0.032 6 (27) 6 (27) 1.000 
Pre-fracture institutionalized2* 0 (0) 3 (2) 1.000 0 (0) 0 (0) N.A. 
Pre-fracture independent ambulatory2* 37 (100) 105 (84) 0.008 22 (100) 22 (100) N.A. 
Evident implant back-out2 20 (54) 41 (34) 0.035 11 (50) 2 (9) 0.004 
Time to implant removal (months) 1 15 (13-17) N.A. N.A. 15 (13-17) N.A. N.A. 
BMI, Body Mass Index; ASA, American Society of Anesthesiologists. 
Differences between the groups were tested with the Mann Whitney U-test (crude analysis) or Wilcoxon signed rank test (matched pair analysis) 
for numeric variables, and the Chi-squared test (crude analysis) or McNemar’s chi-squared test (matched pair analysis) for categorical variables. 
1 Data are presented as median with P25-P75 given between brackets. 
2 Data are presented as number with percentages. 
* This parameter was used to match pairs.
Table 2. Changes in patient self-reported physical functioning after two years follow-up 
 Implant removed 
(N=37) 
Implant retained 
(N=125) 
P-value 
SF-12    
Change Score 2 years -3 (-19-4) -3 (-14-2) 0.700 
Change Physical (PCS) 2 years -6 (-19- -1) -3 (-13-1) 0.167 
Change Mental (MCS) 2 years 3 (-4-9) 1 (-4-6) 0.368 
WOMAC    
Change Score 2 years -3 (-32-0) -4 (-18-1) 0.427 
Change Pain 2 years -5 (-33-0) 0 (-10-0) 0.156 
Change Stiffness 2 years 0 (-38-0) 0 (-25-13) 0.086 
Change Function 2 years -4 (-35-0) -5 (-19-0) 0.676 
SF-12, Short Form 12; WOMAC, Western Ontario McMaster Osteoarthritis Index; PCS, 
Physical Component Summary; MCS, Mental Component Summary. 
Scores were measured at baseline (i.e., pre-fracture) and at two years later. These scores are 
presented in Supplemental table 1. The change in scores between these two moments was 
calculated using the formula: Change Score = Score 2 years – Score baseline. 
Data are presented as median with P25-P75 given between brackets. Differences between the 
groups were tested with the Mann Whitney U-test. 
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Table 3. Effect of implant removal on patient self-reported physical functioning 1 
 Implant removed 
(N=22) 
Implant retained 
(N=22) 
P-value 
SF-12    
Score before removal 99 (87-109) 107 (98-110) 0.062 
Physical (PCS) before removal 44 (35-49) 53 (46-56) 0.005 
Mental (MCS) before removal 57 (48-62) 53 (50-61) 0.910 
Score after removal 104 (92-109) 107 (98-109) 0.236 
Physical (PCS) after removal 48 (42-51) 49 (43-52) 0.548 
Mental (MCS) after removal 56 (48-61) 59 (56-62) 0.050 
Change Score 0 (-4-10) 0 (-2-4) 0.485 
Change Physical (PCS)  2 (-4-14) -4 (-7-0) 0.024 
Change Mental (MCS)  0 (-6-4) 4 (0-6) 0.168 
WOMAC    
Score before removal 82 (62-88) 98 (88-100) 0.001 
Pain before removal 83 (69-90) 100 (95-100) 0.001 
Stiffness before removal 75 (50-91) 100 (75-100) 0.010 
Function before removal 82 (61-88) 98 (89-100) 0.002 
Score after removal 90 (74-98) 93 (87-100) 0.106 
Pain after removal 90 (69-100) 98 (90-100) 0.036 
Stiffness after removal 81 (75-100) 94 (88-100) 0.057 
Function after removal 91 (71-100) 95 (85-100) 0.145 
Change Score  9 (-2-16) 0 (-7-2) 0.019 
Change Pain  5 (-1-11) 0 (-1-1) 0.051 
Change Stiffness  6 (-3-38) 0 (-13-3) 0.176 
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Change Function  10 (-2-18) 0 (-6-3) 0.030 
SF-12, Short Form 12; WOMAC, Western Ontario McMaster Osteoarthritis Index; PCS, 2 
Physical Component Summary; MCS, Mental Component Summary. 3 
Scores were measured at the follow-up moment immediately before implant removal (mostly 4 
12 or 18 months after initial fracture surgery) and after removal (mostly 18 or 24 months after 5 
initial fracture surgery). For the matched control the same follow-up moment was used. The 6 
change in scores between these two moments was calculated using the formula: Change Score 7 
= Score after removal – Score before removal. 8 
Data are presented as median with P25-P75 given between brackets. Differences between the 9 
groups were tested with the Wilcoxon signed rank test. 10 
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Supplemental Table 1. Patient self-reported physical functioning at baseline and after 2 years follow-up 11 
 Total group / 
Crude analysis 
  Matched pair analysis   
 Implant removed 
(N=37) 
Implant retained 
(N=125) 
P-value Implant removed 
(N=22) 
Implant retained 
(N=22) 
P-value 
SF-12       
Score baseline 107 (99-114) 102 (92-110) 0.038 109 (100-114) 111 (100-114) 0.958 
Physical (PCS) baseline 54 (48-57) 51 (43-55) 0.014 55 (49-58) 54 (51-56) 0.741 
Mental (MCS) baseline 54 (48-59) 55 (48-59) 0.997 56 (51-59) 54 (47-61) 0.715 
Score 2 years 106 (87-112) 98 (84-108) 0.219 106 (85-111) 107 (97-113) 0.099 
Physical (PCS) 2 years 48 (36-52) 44 (33-52) 0.563 47 (37-52) 52 (43-57) 0.046 
Mental (MCS)  2 years 58 (47-62) 55 (48-61) 0.296 58 (44-62) 55 (54-62) 0.375 
Change Score -3 (-19-4) -3 (-14-2) 0.700 -5 (-19-2) -3 (-12-5) 0.149 
Change Physical (PCS) -6 (-19- -1) -3 (-13-1) 0.167 -6 (-16- -1) -2 (-12-2) 0.170 
Change Physical (MCS) 3 (-4-9) 1 (-4-6) 0.368 3 (-8-6) 1 (-2-8) 0.274 
WOMAC       
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Score baseline 97 (93-100) 95 (83-99) 0.101 98 (96-100) 98 (98-100) 0.063 
Pain baseline 100 (93-100) 100 (90-100) 0.838 100 (100-100) 100 (100-100) 0.276 
Stiffness baseline 100 (88-100) 88 (75-100) 0.091 100 (88-100) 100 (88-100) 0.593 
Function baseline 99 (93-100) 95 (81-100) 0.047 99 (96-100) 99 (98-100) 0.157 
Score 2 years 91 (65-96) 90 (72-97) 0.889 91 (65-96) 100 (91-100) 0.009 
Pain 2 years 95 (65-100) 95 (85-100) 0.189 95 (65-100) 100 (99-100) 0.009 
Stiffness 2 years 75 (56-100) 81 (63-100) 0.601 75 (50-100) 100 (88-100) 0.015 
Function 2 years 94 (65-98) 90 (67-97) 0.583 94 (65-97) 100 (91-100) 0.024 
Change Score -3 (-32-0) -4 (-18-1) 0.427 -5 (-35- -2) 0 (-5-2) 0.009 
Change Pain -5 (-33-0) 0 (-10-0) 0.156 -5 (-35-0) 0 (0-0) 0.034 
Change Stiffness 0 (-38-0) 0 (-25-13) 0.086 -13 (-38-0) 0 (-13-13) 0.012 
Change Function -4 (-35-0) -5 (-19-0) 0.676 -6 (-35- -1) 0 (-5-1) 0.023 
SF-12, Short Form 12; WOMAC, Western Ontario McMaster Osteoarthritis Index; PCS, Physical Component Score; MCS, Mental Component 12 
Score. Scores were measured at baseline (i.e., pre-fracture) and after 2 years follow-up. The change in scores between these two moments was 13 
calculated using the formula: Change Score = Score at 2 years – Score at baseline. Data are presented as median with P25-P75 between brackets. 14 
Differences between the groups were tested with the Mann Whitney U-test (total group) or Wilcoxon signed rank test (matched pair analysis). 15 
